Cargando empresa
Keep exploring
The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B US$A
NBIXNeurocrine Biosciences, Inc.16,9B US$A+
ELANElanco Animal Health Incorporated13,4B US$A
KNSAKiniksa Pharmaceuticals International, plc8,2B US$A+
LQDALiquidia Corporation5,2B US$A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- Regular traditional Chinese medicine pieces95 %
- Advanced traditional Chinese medicine pieces4 %
Los porcentajes de ingresos son estimaciones para year ended March 31, 2026, no cifras de un informe oficial.
Compite con
- 600518Kangmei Pharmaceutical Co., Ltd.
- 300147Xiangxue Pharmaceutical Co., Ltd.
Qué vende6
Regular traditional Chinese medicine pieces
Medicinal plants processed into forms such as cut pieces or powders, generally prepared by boiling or decoction before use.
Directly-Oral advanced TCMP
Processed herbal medicines made to be taken by mouth without first being boiled as a decoction.
After-Soaking-Oral advanced TCMP
Small sealed bags of herbal material steeped in hot water to make an infusion.
Mostrar 3 más
SanQiFen
A directly swallowed powder made from the roots and rhizomes of notoginseng.
CuYanHuSuo
A directly swallowed powder made from the tubers of Corydalis yanhusuo.
LuXueJing
A directly swallowed product made from dried deer blood.
Quién se lo compra3
- Hospitals, especially traditional Chinese medicine hospitals, buy products for patient care, mainly in Jiangsu province.
- Pharmaceutical wholesalers buy products and distribute them to hospitals and other healthcare distributors.
- As of March 31, 2026, end customers included 46 pharmaceutical companies, 11 chain pharmacies and 12 hospitals (March 31, 2026, high).
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1Relies on medicinal-plant raw materials supplied by vendors in China.
- 2Relies on a limited number of customers; hospitals and pharmaceutical distributors account for important sales channels.
- 3Its business in China depends on contractual arrangements with Taizhou Suxuantang, a variable interest entity, rather than direct ownership of that operating company.
Qué podría salir mal
- 1Losing or reducing sales to a small number of major customers could harm revenue.
- 2Disruptions in the supply of medicinal plants or other raw materials could interrupt production and deliveries.
- 3The company may be unable to enforce its contractual arrangements with Taizhou Suxuantang, or changes in Chinese rules may affect those arrangements or its ability to operate.
Estados financieros completos →
Sobre China SXT Pharmaceuticals, Inc.
China SXT makes traditional Chinese medicine pieces (TCMP) from medicinal plants, including herbs prepared as powders and other forms. In the fiscal year ended March 31, 2026, regular TCMP made up 95.02% of revenue (FY2026, high), while advanced TCMP made up 4.35% (FY2026, high); some advanced products can be swallowed directly or steeped in hot water. Total revenue was $1,138,052 (year ended March 31, 2026, high).
- Sede
- Taizhou, Jiangsu, China
- Fundada en
- 2017
- Empleados
- 56 full-time employees (March 31, 2026, high)
- Cotiza en
- Nasdaq Capital Market
- Cierre del ejercicio
- March 31
Construido a partir de los propios informes de China SXT Pharmaceuticals, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
